|The following article is part of conference coverage from the 2018 AHA Scientific Sessions in Chicago, Illinois. MPR’s staff will be reporting breaking news associated with research conducted by leading experts in cardiology. Check back for the latest news from AHA 2018.|
CHICAGO — For patients with mild hypertriglyceridemia and coronary artery disease or hypercholesterolemia, adding omega-3 fatty acids to their standard therapy reduced the risk of a major adverse cardiovascular event and improved triglyceride levels. These findings were presented at the Scientific Sessions of the American Heart Association, November 10 to 12, 2018.
Researchers conducted a meta-analysis and identified 6 randomized control studies involving patients at high cardiovascular risk with mild hypertriglyceridemia (150-199mg/dL) from Medline, EMBASE, and CENTRAL databases.
Triglyceride levels of the 37,840 patients included in this study were significantly improved by a mean difference of -7.88mg/dL (95% CI, -11.38 to -4.37) over the mean follow-up duration of 38.2±18 months.
The relative risk of a major adverse cardiovascular event and a myocardial infarction were reduced when compared with patients not taking omega-3 fatty acids (relative risk [R], 0.85; 95% CI, 0.74-0.98 and RR, 0.76; 95% CI, 0.67-0.87, respectively).
The relative risk for all-cause mortality, cardiovascular mortality, stroke, and revascularization was comparable between the patients taking omega-3 fatty acid and the controls.
Researchers concluded “[o]mega-3 fatty acids improve triglyceride levels and reduce [major adverse cardiovascular events] in high-risk patients with mild hypertriglyceridemia.”
For more coverage of AHA 2018, click here.
Rahman HU, Khan SU, Hammad T, Kaluski E. Effect of omega-3 fatty acids on cardiovascular outcomes in high risk patients with mild hypertriglyceridemia: a meta-analysis. Presented at: AHA 2018; November 10-12, 2018; Chicago, Illinois. Abstract Su1269/1269.
This article originally appeared on The Cardiology Advisor